Страна: Армения
Язык: английский
Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
butamirate (butamirate citrate)
Novartis Consumer Health S.A.
butamirate (butamirate citrate)
1,5mg/ml
syrup
OTC
Novartis Consumer Health SA CH-1260 Nyon, Switzerland Global Regulatory Affairs Global Labelling & Compliance SINECOD ® syrup Butamirate citrate CORE SUMMARY OF PRODUCT CHARACTERISTICS (SMPC) Author(s): Jean-Michel Casado, Helena Beauvallon Document status: FINAL GLC approval date: 11 Jun 2009 GLC tracking ID: Amendment date(s): Release date: Next update date: Jun 2014 Number of pages: 7 Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis Novartis Consumer Health SA CONFIDENTIAL Page 2 Core SmPC GLC: 11 Jun 2009 Sinecod 1 NAME OF THE MEDICINAL PRODUCT ....................................................................... 3 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ............................................. 3 3 PHARMACEUTICAL FORM ............................................................................................ 3 4 CLINICAL PARTICULARS .............................................................................................. 3 4.1 Therapeutic indications ............................................................................................ 3 4.2 Posology and method of administration .................................................................. 3 4.3 Contraindications ..................................................................................................... 3 4.4 Special warnings and precautions for use ................................................................ 3 4.5 Interaction with other medicinal products and other forms of interaction .............. 4 4.6 Pregnancy and lactation ........................................................................................... 4 4.7 Effects on ability to drive and use machines ........................................................... 4 4.8 Undesirable effects .................................................................................................. 4 4.9 Overdose ............................................................................ Прочитать полный документ